Impact of lipophilic <i>vs</i> hydrophilic statins on the clinical outcome and biomarkers of remodelling in heart failure patients: A prospective comparative randomized study

Aims There are insufficient direct comparative studies addressing the impact of type statin on their respective efficacy in heart failure (HF). The aim current study was to compare effects lipophilic (atorvastatin) vs hydrophilic (rosuvastatin) left ventricular function, inflammatory and fibrosis biomarkers patients with chronic HF. Methods This a prospective, randomized, comparative, parallel study. A total 85 HF optimized guideline directed therapy were randomized receive either atorvastatin 40 mg (n = 42) or rosuvastatin 20 43) for 6 months. Baseline follow-up assessment included 2D echocardiography, measurement N-terminal pro-brain natriuretic peptide, interleukin-6 soluble suppression tumorigenicity 2 (sST2) levels, liver enzymes lipid profile. Results increase ejection fraction significantly higher group compared (6.5% [3–11] 4% [2–5], P .006). reduction end diastolic systolic volume comparable between groups. decrease sST2 levels pg/mL (?255 [?383 ?109.8 ? 151 [?216 ?69], .003). significant peptide both groups, yet Conclusion results suggest that is superior increasing reducing marker patients. Trial registration ID: NCT03255044, registered 21 August 2017.